Boston Pharmaceuticals gets rights to Daiichi's preclinical RET inhibitor for solid cancers
Executive Summary
Daiichi Sankyo Co. Ltd. granted Boston Pharmaceuticals Inc. global rights to develop, manufacture, and sell its late-preclinical-stage RET inhibitor DS5010 for solid tumors.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Reverse Licensing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice